Mechanisms regulating resistance to inhibitors of topoisomerase II

Frontiers in Pharmacology

Volumn 4 AUG, Issue , 2013, Pages

  Ganapathi, Ram N ^a   Ganapathi, Mahrukh K ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Calmodulin inhibitors; Casein kinase I; Drug resistance; Topo II phosphorylation; Topoisomerase II

Indexed keywords

AMSACRINE; ANTHRACYCLINE; CALCIUM; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE (ATP HYDROLYSING) ALPHA; DOXORUBICIN; ETOPOSIDE; GENISTEIN; GYRASE INHIBITOR; IRINOTECAN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; TENIPOSIDE; TOPOTECAN; UNCLASSIFIED DRUG; VINCRISTINE;

ARTICLE; BREAST CANCER; CALCIUM CELL LEVEL; CELL DIVISION; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; ENZYME PHOSPHORYLATION; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; LUNG SMALL CELL CANCER; NONHUMAN; PHENOTYPE; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84882993972     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00089     Document Type: Article

References (101)

1. Ackerman, P., Glover, C. V., and Osheroff, N. (1985). Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc. Natl. Acad. Sci. U.S.A. 82, 3164-3168. doi: 10.1073/pnas.82.10.3164
2. Bertrand, R., Kerrigan, D., Sarang, M., Pommier, Y., et al. (1991). Cell death induced by topoisomerase inhibitors. Role of calcium in mammalian cells. Biochem. Pharmacol. 42, 77-85. doi: 10.1016/0006-2952(91)90683-V
3. Bhushan, A., Kermode, J. C., Posada, J., and Tritton, T. R. (1989). Anthracycline resistance. Cancer Treat. Res. 48, 55-72. doi: 10.1007/978-1-4613-1601-5_5
4. Biedler, J. L., and Riehm, H. (1980). Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res. 30, 1171-1184. doi: 10.1158/1078-0432.CCR-09-2471
5. Brase, J. C., Schmidt, M., Fischbach, T., Sültmann, H., Bojar, H., Koelbl, H., et al. (2010). ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction. Clin. Cancer Res. 16, 2391-2401. doi: 10.1021/bi00253a001
6. Burden, D. A., Goldsmith, L. J., and Sullivan, D. M. (1993). Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II. Biochem. J. 293, 297-304.
7. Burden, D. A., and Sullivan, D. M. (1994). Phosphorylation of the a- and β- isoforms of DNA topoisomerase II is qualitively different in interphase and mitosis in Chinese hamster ovary Cells. Biochemistry 33, 14651-14655. doi: 10.1021/bi00253a001
8. Cardenas, M. E., Dang, Q., Glover, C. V., and Gasser, S. M. (1992). Casein kinase II phosphorylates the eukaryotic-specific C-terminal domain of topoisomerase II in vivo. EMBO J. 11, 1788-1796.
9. Cardenas, M. E., and Gasser, S. M. (1993). Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. J. Cell Sci. 104, 219-225.
10. Cardenas, M. E., Walter, R., Hanna, D., and Gasser, S. M. (1993). Casein kinase II copurifies with yeast DNA topoisomerase II and re-activates the dephosphorylated enzyme. J. Cell Sci. 104, 533-543.
11. Carlson, R. W., O'Neill, A. M., Goldstein, L. J., Sikic, B. I., Abramson, N., Stewart, J. A., et al. (2006). A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest. 24, 677-681. doi: 10.1080/07357900600981349
12. Carter, S. K. (1975). Adriamycin-a review. J. Natl. Cancer Inst. 55, 1265-1274.
13. Center, M. S. (1993). Non-P-glycoprotein multidrug resistance in cell lines which are defective in the cellular accumulation of drugs. Cytotechnology 12, 109-125. doi: 10.1007/BF00744660
14. Chen, A. Y., and Liu, L. F. (1994). DNA Topoisomerases; essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 36, 191-218. doi: 10.1146/annurev.pa.34.040194.001203
15. Chen, M., and Beck, W. T. (1995). DNA topoisomerase II expression, stability, and phosphorylation in two VM-26-resistant human leukemic CEM sublines. Oncol. Res. 7, 103-111.
16. Chikamori, K., Grabowski, D. R., Kinter, M., Willard, B. B., Yadav, S., Aebersold, R. H., et al. (2003). Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulatesenzymatic activity and drug sensitivity. J. Biol. Chem. 278, 12696-12702. doi: 10.1074/jbc.M300837200
17. Chikamori, K., Grozav, A. G., Kozuki, T., Grabowski, D., Ganapathi, R., Ganapathi, M. K., et al. (2010). DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy. Curr. Cancer Drug Targets 10, 758-771. doi: 10.2174/156800910793605785
18. Chin, K. V., Pastan, I., and Gottesman, M. M. (1993). Function and regulation of the human multidrug resistance gene. Adv. Cancer Res. 60, 157-180. doi: 10.1016/S0065-230X(08)60825-8
19. Chung, T. D., Drake, F. H., Tan, K. B., Per, S. R., Crooke, S. T., Mirabelli C. K., et al. (1989). Characterization and immunological identification of cDNA clones encloding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. U.S.A. 86, 9431-9435. doi: 10.1073/pnas.86.23.9431
20. Cole, S. P., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., et al. (1994). Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54,5902-5910.
21. Curt, G. A., Clendeninn, N. J., and Chabner, B. A. (1984). Drug resistance in cancer. Cancer Treat. Rep. 68, 87-99.
22. Danks, M. K., Qiu, J., Catapano, C. V., Schmidt, C. A., Beck, W. T., Fernandes, D. J., et al. (1994). Subcellular distribution of the a and β topoisomerase II-DNA complexes stabilized by VM-26. Biochem. Pharmacol. 48, 1785-1795. doi: 10.1016/0006-2952(94)90465-0
23. Danks, M. K., Warmoth, M. R., Friche, E., Granzen, B., Bugg, B. Y., Harker, W. G., et al. (1993). Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 53, 1373-1379.
24. D'Arpa, P., Beardmore, C., and Liu, L. F. (1990). Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50, 6919-6924.
25. de Jong, S., Kooistra, A. J., de Vries, E. G., Mulder, N. H., Zijlstra, J. G., et al. (1993). Topoisomerase II as a target of VM-26 and 4'-(9-Acridinylamino) methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. Cancer Res. 53, 1064-1071.
26. DeVore, R. F., Corbett, A. H., and Osheroff, N. (1992). Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino) methane-sulfon-m-anisidide. Cancer Res. 52, 2156-2161.
27. Di Leo, A., Desmedt, C., Bartlett, J. M., Piette, F., Ejlertsen, B., Pritchard, K. I., et al. (2011). HER2 and TOP2A as predictivemarkers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. 12, 1134-1142. doi: 10.1016/S1470-2045(11)70231-5
28. Doroshow, J. H., Akman, S., Chu, F. F., and Esworthy, S. (1990). Role of the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer quinones. Pharmacol. Ther. 47, 359-370. doi: 10.1016/0163-7258(90)90062-7
29. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., Mirabelli, C. K., et al. (1989). Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 28, 8154-8160. doi: 10.1021/bi00446a029
30. Du, Y., Zhou, Q., Yin, W., Zhou, L., Di, G., Shen, Z., et al. (2011). The role of topoisomerase IIa in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Breast Cancer Res. Treat. 129, 839-848. doi: 10.1007/s10549-011-1694-9
31. Ejlertsen, B., Jensen, M. B., Nielsen, K. V., Balslev, E., Rasmussen, B. B., Willemoe, G. L., et al. (2010). HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. J. Clin. Oncol. 28, 984-990. doi: 10.1200/JCO.2009.24.1166
32. Endicott, J. A., and Ling, V. (1989). The biochemistry of P-glycoprotein mediated multidrug resistance. Ann. Rev. Biochem. 58, 137-171. doi: 10.1146/annurev.bi.58.070189.00 1033
33. Estey, E., Adlakha, R. C., Hittelman, W. N., and Zwelling, L. A. (1987). Cell cycle state dependent variations in drug-induced topoisomerase II mediated DNA cleavage and cytotoxicity. Biochemistry 26, 4338-4344. doi: 10.1021/bi00388a023
34. Feldhoff, P. W., Mirski, S. E. L., Cole, S. P. C., and Sullivan, D. M. (1994). Altered subcellular distribution of topoisomerase IIa in a drug-resistant human small cell lung cancer cell line. Cancer Res. 54, 756-762.
35. Fernandes, D. J., Danks, M. K., and Beck, W. T. (1990). Decreased nuclear matrix DNA topoisomerase II in human leukemia cells resistant to VM-26 and m-AMSA. Biochemistry 29, 4235-4241. doi: 10.1021/bi00469a028
36. Ford, J. M., and Hait, W. N. (1990). Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 42, 155-199.
37. Froelich-Ammon, S. J., and Osheroff, N. (1995). Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270, 21429-21432. doi: 10.1074/jbc.270.37.21429
38. Fry, A. M., Chresta, C. M., Davies, S. M., Walker, M. C., Harris, A. L., Hartley, J. A., et al. (1991). Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res. 51, 6592-6595.
39. Ganapathi, R., Budd, T., and Bukowski, R. (1993a). "Modulation of clinical doxorubicin resistance: application of laboratory concepts and future directions" in The Mechanism and New Approach on Drug Resistance of Cancer Cells, eds T. Miyazaki, F. Takaku, and K. Sakurada (Amsterdam: Elsevier Science Publishers, B.V.), 267-278.
40. Ganapathi, R., Zwelling, L., Constantinou, A., Ford, J., Grabowski, D., et al. (1993b). Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Biochem. Biophys. Res. Commun. 192, 1274-1280. doi: 10.1006/bbrc.1993.1554
41. Ganapathi, R., Constantinou, A., Kamath, N., Dubyak, G., Grabowski, D., Krivacic, K., et al. (1996). Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Mol. Pharmacol. 50, 243-248.
42. Ganapathi, R., and Grabowski, D. (1983). Enhancement of sensitivity to Adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine. Cancer Res. 43, 3696-3699.
43. Ganapathi, R., and Grabowski, D. (1988). Differential effect of the calmodulin inhibitor trifluoperazine in modulating cellular accumulation, retention and cytotoxicity of doxorubicin in progressively doxorubicin resistant L1210 mouse leukemia cells: lack of correlation between cellular doxorubicin levels and expression of resistance. Biochem. Pharmacol. 37, 185-193. doi: 10.1016/0006-2952(88)90716-2
44. Ganapathi, R., Grabowski, D., Rouse, W., and Riegler, F. (1984). Differential effect of the calmodulin inhibitor trifluoperazine on the cellular accumulation, retention and cytotoxicity of anthracyclines in doxorubicin (adriamycin) resistant P388 mouse leukemia cells. Cancer Res. 44, 5056-5061.
45. Ganapathi, R., Grabowski, D., Schmidt, H., Bell, D., and Melia, M. (1987). Characterization, in vitro and in vivo of progressively adriamycin-resistant B16-BL6 mouse melanoma cells. Cancer Res. 47, 3464-3468.
46. Ganapathi, R., Grabowski, D., Sweatman, T. W., Seshadri, R., and Israel, M. (1989). N-benzyl-adriamycin-14-valerate versus progressively doxorubicin-resistant murine tumors: cellular pharmacology and characterization of cross-resistance in vitro and in vivo. Br. J. Cancer 60, 819-826. doi: 10.1038/bjc.1989.373
47. Ganapathi, R., Kamath, N., Constantinou, A., Grabowski, D., Ford, J., Anderson, A., et al. (1991a). Effect of the calmodulin inhibitor trifluoperazine on phosphorylation of P-glycoprotein and topoisomerase II: relationship to modulation of subcellular distribution, DNA damage and cytotoxicity of doxorubicin in multidrug resistant L1210 mouse leukemia cells. Biochem. Pharmacol. 41, R21-R26. doi: 10.1016/0006-2952(91)90115-L
48. Ganapathi, R., Kuo, T., Teeter, L., Grabowski, D., and Ford, J. (1991b). Relationship between expression of P-glycoprotein and efficacy of trifluoperazine in multidrug-resistant cells. Mol. Pharmacol. 39, 1-8.
49. Ganapathi, R., Schmidt, H., Grabowski, D., Melia, M., Ratliff, N., et al. (1988). Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance. Br. J. Cancer 58, 335-340. doi: 10.1038/bjc.1988.214
50. Grozav, A. G., Chikamori, K., Kozuki, T., Grabowski, D. R., Bukowski, R. M., Willard, B., et al. (2009). Casein kinase I delta/epsilonphosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavageactivity. Nucleic Acids Res. 37, 382-392. doi: 10.1093/nar/gkn934
51. Harker, W. G., Slade, D. L., Drake, F. H., and Parr, R. L. (1991). Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform. Biochemistry 30, 9953-9961. doi: 10.1021/bi00105a020
52. Hashimoto, Y., and Soderling, T. R. (1989). Regulation of calcineurin by phosphorylation. Identification of the regulatory site phosphorylated by Ca2+/calmodulin-dependent protein kinase II and protein kinase C. J. Biol. Chem. 264, 16524-16529.
53. Heck, M. M. S., Goldsmith, L. J., and Sullivan, D. M. (1989). In vivo phosphorylation of the 170-kDa form of eukaryotic DNA topoisomerase II cell cycle analysis. J. Biol. Chem. 264, 15161-15164.
54. Hertel, P. B., Tu, D., Ejlertsen, B., Jensen, M. B., Balslev, E., Jiang, S., et al. (2012). TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Res. Treat. 132, 225-234. doi: 10.1007/s10549-011-1896-1
55. Herzog, C. E., Holmes, K. A., Tuschong, L. M., Ganapathi, R., and Zwelling, L. A. (1998). Absence of topoisomerase IIβ in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIa. Cancer Res. 58, 5298-5300.
56. Hinds, M., Deisseroth, K., Mayes, J., Altschuler, E., Jansen, R., Ledley, F. D., et al. (1991). Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res. 51, 4729-4733.
57. Hsiang, Y.-W., and Liu, L. F. (1989). Evidence for the reversibility of cellular DNA lesion induced by mammalian topoisomerase II poisons. J. Biol. Chem. 264, 9713-9715.
58. Juenke, J. M., and Holden, J. A. (1993). The distribution of DNA topoisomerase II isoforms in differentiated adult mouse tissues. Biochim. Biophys. Acta. 1216, 191-196. doi: 10.1016/0167-4781(93)90144-3
59. Kawachi, K., Sasaki, T., Murakami, A., Ishikawa, T., Kito, A., Ota, I., et al. (2010). The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy. Pathol. Res. Pract. 206, 156-162. doi: 10.1016/j.prp.2009.10.009
60. Kawamura, K., Grabowski, D., Krivacic, K., Hidaka, H., Ganapathi, R., et al. (1996a). Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation. Biochem. Pharmacol. 52, 1903-1909. doi: 10.1016/S0006-2952(96)00692-2
61. Kawamura, K. I., Grabowski, D., Weizer, K., Bukowski, R., Ganapathi, R., et al. (1996b). Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Br. J. Cancer 732, 183-8. doi: 10.1038/bjc.1996.33
62. Kessel, D., Botterill, V., and Wodinsky, I. (1968). Uptake and retention of daunomycin by mouse leukemic cells as factors in drug response. Cancer Res. 28, 938-941.
63. Kimura, K., Nozaki, N., Saijo, M., Kikuchi, A., Ui, M., and Enomoto, T. (1994a). Identification of the nature of modification that causes the shift of DNA topoisomerase IIβ to apparent higher molecular weight forms in the M Phase. J. Biol. Chem. 269, 24523-24526.
64. Kimura, K., Saijo, M., Ui, M., and Enomoto, T. (1994b). Growth state-and cell cycle-dependent fluctuation in the expression of two forms of DNA topoisomerase II and possible specific modification of the higher molecular weight form in the M phase. J. Biol. Chem. 269, 1173-1176.
65. Kimura, K., Saijo, M., Tanaka, M., Enomoto, T., et al. (1996). Phosphorylation-independent stimulation of DNA topoisomerase IIa activity. J. Biol. Chem. 271, 10990-10995. doi: 10.1074/jbc.271.18.10990
66. Klee, C. B., Draetta, G. F., and Hubbard, M. J. (1988). Calcineurin. Adv. Enzymol. 61, 149-200.
67. Kohno, K., Danks, M. K., Matsuda, T., Nitiss, J. L., Kuwano, M., and Beck, W. T. (1995). A novel mutation of DNA-topoisomerase II-alpha gene in an etoposide-resistant human cancer cell line. Cell. Pharmacol. 2, 87-90.
68. Kolitz, J. E., George, S. L., Marcucci, G., Vij, R., Powell, B. L., Allen, S. L., et al. (2010). P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116, 1413-1421. doi: 10.1182/blood-2009-07-229492
69. Kroll, D. J., and Rowe, T. C. (1991). Phosphorylation of DNA topoisomerase II in a human tumor cell line. J. Biol. Chem. 266, 7957-7961.
70. Kubo, A., Yoshikawa, A., Hirashima, T., Masuda, N., Takada, M., Takahara, J., et al. (1996). Point mutations of the topoisomerase IIa gene in patients with small cell lung cancer treated with etoposide. Cancer Res. 56, 1232-1236.
71. Ling, V., and Thompson, L. H. (1974). Reduced permeability of CHO cells as a mechanism of resistance to colchicine. J. Cell. Physiol. 83, 103-116. doi: 10.1002/jcp.1040830114
72. Louie, K. G., Hamilton, T. C., Winker, M. A., Behrens, B. C., Tsuruo, T., Klecker, R. W. Jr., et al. (1986). Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem. Pharmacol. 35, 467-472. doi: 10.1016/0006-2952(86)90221-2
73. Lum, B. L., Fisher, G. A., Brophy, N. A., Yahanda, A. M., Adler, K. M., Kaubisch, S., et al. (1993). Clinical trials of modulation of multidrug resistance. Pharamcokinetic and pharmacodynamic considerations. Cancer 72, 3502-3514. doi: 10.1002/1097-0142(19931201)72:11
74. Mirski, S. E. L., Evans, C. D., Almquist, K. C., Slovak, M. L., and Cole, S. P. C. (1993). Altered topoisomerase IIa in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res. 53, 4866-4873.
75. Myers, C. E., and Chabner, B. A. (1990). "Anthracyclines," in Cancer Chemotherapy: Principles and Practice, eds B. A. Chabner and J. M. Collins (Philadelphia: J.B. Lippincott Co.), 356-381.
76. Nelson, W. G., Liu, L. F., and Coffey, D. S. (1986). Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature 322, 187-189. doi: 10.1038/322187a0
77. Nikolényi, A., Sükösd, F., Kaizer, L., Csörgo, E., Vörös, A., Uhercsák, G., et al. (2011). Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Oncology. 80, 269-277. doi: 10.1159/000329038
78. Oakman, C., Moretti, E., Galardi, F., Santarpia, L., and Di Leo, A. (2009). The role of topoisomerase II alpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat. Rev. 35, 662-667. doi: 10.1016/j.ctrv.2009.08. 006
79. O'Malley, F. P., Chia, S., Tu, D., Shepherd, L. E., Levine, M. N., Huntsman, D., et al. (2011). Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Res. Treat. 128, 401-409. doi: 10.1007/s10549-011-1511-5
80. Osheroff, N. (1987). Role of divalent cation in topoisomerase II mediated reactions. Biochemistry 26, 6402-6406. doi: 10.1021/bi00394a015
81. Osheroff, N., and Zechiedrich, E. L. (1987). Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: trapping the covalent enzyme-DNA complex in an active form. Biochemistry 26, 4303-4309. doi: 10.1021/bi00388a018
82. Pommier, Y., Leteurtre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., et al. (1994). Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12, 530-542. doi: 10.3109/07357909409021413
83. Ritke, M. K., Murray, N. R., Allan, W. P., Fields, A. P., and Yalowich, J. C. (1994a). Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 Cells. Mol. Pharmacol. 46, 58-66.
84. Ritke, M. K., Roberts, D., Allan, W. P., Raymond, J., Bergoltz, V. V., Yalowich, J. C., et al. (1994b). Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells. Br. J. Cancer 69, 687-697. doi: 10.1038/bjc.1994.131
85. Ritke, M. K., Murray, N. R., Allan, W. P., Fields, A. P., and Yalowich, J. C. (1995). Hypophosphorylation of topoisomerase II in etoposide(VP-16)-resistant human leukemia K562 cells is associated with reduced levels of βII protein kinase C. Mol. Pharmacol. 48, 798-805.
86. Sacks, D. B., Mazus, B., and Joyal, J. L., et al. (1995). The activity of calmodulin is altered by phosphorylation: modulation of calmodulin function by the site of phosphate incorporation. Biochem. J. 312, 197-204.
87. Sahyoun, N., Wolf, M., Besterman, J., Hsieh, T., Sander, M., LeVine, H. III., et al. (1986). Protein kinase C phosphorylates topoisomerase II: Topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc. Natl. Acad. Sci. 83, 1603-1607. doi: 10.1073/pnas.83.6.1603
88. Saijo, M., Enomoto, T., Hanaoka, F., and Ui, M. (1990). Purification and characterization of type II DNA topoisomerase from mouse FM3A cells: phosphorylation of topoisomerase II and modification of its activity. Biochemistry 29, 583-590. doi: 10.1021/bi00454a036
89. Saijo, M., Ui, M., and Enomoto, T. (1992). Growth state and cell cycle dependent phosphorylation of DNA topoisomerase II in swiss 3T3 cells. Biochemistry 31, 359-363. doi: 10.1021/bi00117a007
90. Siegfried, J. M., Burke, T. G., and Tritton, T. R. (1985). Cellular transport of anthracyclines by passive diffusion. Implications for drug resistance. Biochem. Pharmacol. 34, 593-598. doi: 10.1016/0006-2952(85) 90251-5
91. Slater, L. M., Murray, S. L., Wetzel, M. W., Wisdom, R. M., and DuVall, E. M. (1982). Verapamil restoration of daunorubicin responsiveness in daunorubicin resistant Ehrlich ascites carcinoma. J. Clin. Invest. 70, 1131-1134. doi: 10.1172/JCI110702
92. Sullivan, D. M., Glisson, B. S., Hodges, P. K., Smallwood-Kentro, S., and Ross, W. E. (1986). Proliferation dependence of topoisomerase II mediated drug action. Biochemistry 25, 2248-2256. doi: 10.1021/bi00356a060
93. Tabata, M., Tabata, R., Grabowski, D. R., Bukowski, R. M., Ganapathi, M. K., Ganapathi, R., et al. (2001). Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human non-small cell lung carcinoma. J. Biol. Chem. 276, 8029-8036. doi: 10.1074/jbc.M009831200
94. Takano, H., Kohno, K., Matsuo, K., Matsuda, T., and Kuwano, M. (1992). DNA topoisomerase-targeting antitumor agents and drug resistance. AntiCancer Drugs 3, 323-330. doi: 10.1097/00001813-199208000-00002
95. Takano, H., Kohno, K., Ono, M., Uchida, Y., and Kuwano, M. (1991). Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB Cells. Cancer Res. 51, 3951-3957.
96. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y. (1982). Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42, 4730-4733.
97. Watt, P. M., and Hickson, I. D. (1994). Structure and function of type II DNA topoisomerases. Biochem. J. 303, 681-695.
98. Wells, N. J., Addison, C. M., Fry, A. M., Ganapathi, R., and Hickson, I. D. (1994). Serine 1524 is a major site of phosphorylation on human topoisomerase IIa protein in vivo and is a substrate for casein kinase II in vitro. J. Biol. Chem. 269, 29746-29751.
99. Woessner, R. D., Chung, T. D., Hofmann, G. A., Mattern, M. R., Mirabelli, C. K., Drake, F. H., et al. (1990). Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res. 50, 2901-2908.
100. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. (1989). Proliferation and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2, 209-216.
101. Zini, N., Santi, S., Ognibene, A., Bavelloni, A., Neri, L. M., Valmori, A., et al. (1994). Discrete localization of different DNA topoisomerases in HeLa and K562 cell nuclei and subnuclear fractions. Exp. Cell Res. 210, 336-348. doi: 10.1006/excr.1994.1046